
COVID-19: Moderna reports promising interim results
On Monday, Moderna Inc. announced that two 100µg shots of its mRNA COVID-19 vaccine candidate mRNA-1273 showed an efficacy of 94,5%, according to an...

Biotech companies launch Biotech Austria
According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...

Cell and gene therapy specialist Minaris expanding
In Europe, the Showa Denko Materials Co., Ltd. subsidiary will invest US$40.7 million to build a new state-of-the-art facility in proximity to an...

3P Bio to manufacture SpyBiotech vaccine
Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Protein Brewery raise €22m in Series A
The Series A investment round, which brings the total amount invested into the Dutch food and feed maker to €26m, was led by Novo Holdings. New...